Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries

Alten, Rieke; Feist, Eugen; Lorenz, Hanns‐Martin; Nüßlein, H.; Voll, Reinhard; Chartier, M.; Elbez, Yedid; Rauch, C.

doi:10.1007/s10067-019-04648-5

Cited by 4 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding drug persistence, our results at 12 months are comparable to those of the observational ACTION study (n = 2350), which reported pursuance of intravenous ABA in 78% in bDMARDS naïve patients, and in 70% of patients with failed bDMARD therapy [18]. Conversely, drug persistence at 24 months was similar, at 48% [19,20].…”

Section: Discussionsupporting

confidence: 80%

Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network

Salmon

Letarouilly²,

Goëb

et al. 2020

JCM

View full text Add to dashboard Cite

Objectives: Data on abatacept (ABA) persistence in routine practice are limited. We aimed to study ABA persistence rates at 12 months, according to the date of initiation, and to analyze the factors associated with persistence at 12 months. Methods: We performed an observational, ambispective, multi-center study from January 2008 to July 2016, based on the French-RIC Network. We defined three groups of patients followed up for rheumatoid arthritis (RA), according to the date of initiation of ABA therapy: Group 1 (from 2007 to 31 July 2010: ABA indicated after anti-TNF failure); Group 2 (from 1 August 2010 to 31 March 2014: ABA indicated after conventional antirheumatic drugs failure); Group 3 (from 1 April 2014 to 1 July 2016: ABA available by the subcutaneous injection). Results: Among 517 patients who initiated ABA, drug persistence at 12 months was 68%. The only factor significantly associated with persistence rate at 12 months was C-reactive protein (CRP) < 10 mg/L at ABA initiation (odds ratio (OR) 0.6, 95% confidence interval 0.3–0.9; p = 0.0016). There was no significant difference in drug persistence according to date of initiation, the line of biological disease-modifying antirheumatic drugs (bDMARD) therapy or the route of administration. Conclusions: In routine practice, over time, ABA has come to be initiated earlier in the course of therapy for RA in France. Abatacept persistence is similar to that reported in the Orencia Rheumatoid Arthritis (ORA) registry, and does not differ according to the date of initiation. The only factor found to be associated with the persistence rate at 12 months was CRP < 10 mg/L at ABA initiation.

show abstract

Section: Discussionsupporting

confidence: 80%

Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network

Salmon

Letarouilly²,

Goëb

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…In our study, two-thirds (66.9%) of the patients were bDMARD-n, compared with 25.3%-30.0% of patients who were biologic-naïve from the ACTION study. 12 Our finding that previous bDMARD treatment was predictive of abatacept discontinuation is consistent with those from Finckh et al 20 It has been suggested that variations in comorbidities could affect abatacept retention. 12 Comorbidities such as resolved HBV (44.8%), peptic ulcer disease (16.6%), and liver disease (9.0%) were common among patients in our study, whereas a UK study reported hypertension (20.7%), asthma (14.1%), and diabetes (7.0%) as common comorbidities.…”

Section: Discussionsupporting

confidence: 90%

“…9,10 The 3-year retention rate for abatacept was 43.9%-60.7% in Japan, 7,11 and the 2-year retention rate was 39.9% in Germany. 12 Additionally, a 9-year follow-up study in Canada (Rhumadata registry) found that the retention rate for abatacept as a second-line treatment was better than the rate for tumor necrosis factor (TNF) inhibitors. 13 Clinical outcomes of patients receiving abatacept in routine practice are limited in Taiwan.…”

Section: Introductionmentioning

confidence: 99%

Abatacept retention and clinical effectiveness in patients with rheumatoid arthritis in a real‐world setting in Taiwan

Chen,

Li,

Fang

et al. 2024

Int J of Rheum Dis

View full text Add to dashboard Cite

AimTo evaluate real‐world abatacept retention and clinical outcomes in patients with rheumatoid arthritis in Taiwan.MethodsThis prospective, observational study enrolled patients with rheumatoid arthritis aged ≥20 years who received abatacept in real‐world practice. The primary endpoint was the abatacept retention rate at 24 months. Patients were categorized into subgroups based on abatacept treatment status and previous biological disease‐modifying antirheumatic drug (bDMARD) therapy. Risk factors affecting abatacept retention were determined by regression analysis.ResultsA total of 212 patients were enrolled. The overall abatacept retention rate at 24 months among all patients was 59.9% (95% confidence interval 53.0%–66.6%). Patients who were ongoing users of abatacept and bDMARD‐naïve had the highest retention rate (76.3%); of these, 31.6% achieved low disease activity or remission after 2 years. Previous treatment with bDMARDs was associated with an increased risk of abatacept discontinuation (hazard ratio 1.99; p = .002). The most common reasons for abatacept discontinuation were drug switch (11.3%) and loss to follow‐up (6.1%). Abatacept was well‐tolerated with no new safety signals.ConclusionThe 24‐month retention rate of abatacept was 59.9%; abatacept was associated with improved clinical outcomes and was well‐tolerated in the real‐world setting in Taiwan.

show abstract

“…While we reported retention rates by treatment line and country, clinical outcomes were only reported for Germany and all countries pooled owing to small sample sizes in the Austria and Switzerland cohorts. Overall, abatacept was well tolerated over 2 years in this analysis, with no new safety signals, consistent with the results of previous analyses [ 17 , 24 , 30 ].…”

Section: Discussionsupporting

confidence: 89%

Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus

et al. 2023

Self Cite

View full text Add to dashboard Cite

Introduction/objectives The ASCORE study on treatment for rheumatoid arthritis (RA) showed better retention and clinical response rates for abatacept as first-line versus later-line therapy. This post hoc analysis of ASCORE assessed 2-year retention, efficacy, and safety of subcutaneous (SC) abatacept in Germany, Austria, and Switzerland. Methods Adults with RA who initiated SC abatacept 125 mg once weekly were assessed. Primary endpoint was abatacept retention rate at 2 years. Secondary endpoints: proportions of patients with low disease activity (LDA)/remission per Disease Activity Score in 28 joints based on erythrocyte sedimentation rate (≤ 3.2), Simplified Disease Activity Index (≤ 11), and Clinical Disease Activity Index (≤ 10). Outcomes were analyzed by treatment line and serostatus. Results For the pooled cohort, the 2-year abatacept retention rate was 47.6%; retention was highest in biologic-naïve patients (50.5% [95% confidence interval 44.9, 55.9]). Patients seropositive for both anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF; + / +) at baseline had a higher 2-year abatacept retention rate than patients with single seropositivity for either APCA or RF or double-seronegativity (− / −), irrespective of treatment line. At 2 years, a higher proportion of patients who were biologic-naïve were in LDA/remission than patients with one or ≥ two prior biologics. Conclusion A higher proportion of patients with + / + RA (compared with − / − RA) had abatacept retention after 2 years. Early identification of patients with seropositive RA may facilitate a precision-medicine approach to RA treatment, leading to a higher proportion of patients in LDA/remission. Trial registration number NCT02090556; date registered: March 18, 2014 (retrospectively registered). Key Points• This post hoc analysis of a German-speaking subset of European patients with RA from the global ASCORE study (NCT02090556) showed that retention of SC abatacept within this subset was 47.6%, with good clinical outcomes after 2 years.• Patients with double-seropositive RA (ACPA and RF positive) had higher retention of abatacept than patients with double-seronegative RA (ACPA and RF negative). Retention and clinical responses were highest for patients who were biologic-naïve compared with patients who had one or ≥ two prior biologic treatments.• These real-world data may be useful for clinicians in informing individualized treatment pathways for patients with RA, and fostering superior disease control and clinical outcomes.

show abstract

Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries

Cited by 4 publications

References 20 publications

Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network

Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network

Abatacept retention and clinical effectiveness in patients with rheumatoid arthritis in a real‐world setting in Taiwan

Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus

Contact Info

Product

Resources

About